Preparing for the Future: Calling Attention to Products Coming Off-Patent and Devising Forward-Thinking Portfolio Strategies

June 29, 2022 3:15pm

Tara Rahemba
Executive Director, IP Counsel
Alexion, AstraZeneca Rare Disease

Alicia A. Russo
Venable LLP

Chad J. Peterman
Partner, Litigation Department
Paul Hastings, LLP

  • Calling attention to the products coming off-patent
    • Analyzing approved and marketed biosimilars while looking ahead and considering clinical insights, pricing and dosages
  • Predicting what problems future competitors may run into with respect to their IP profiles
  • Forecasting which segments or regions will drive market growth
  • Reviewing key sustainability tactics adopted by leading market players
  • Evaluating the impact of off-patent drugs on competition and growth strategies
  • Developing techniques for an accurate assessment of the current value of your portfolio while devising forward-thinking product strategies